CECCON, MONICA
 Distribuzione geografica
Continente #
NA - Nord America 2.454
EU - Europa 1.319
AS - Asia 511
AF - Africa 4
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 4.296
Nazione #
US - Stati Uniti d'America 2.412
DE - Germania 289
IT - Italia 250
CN - Cina 207
IE - Irlanda 190
SE - Svezia 180
SG - Singapore 173
RU - Federazione Russa 95
UA - Ucraina 89
GB - Regno Unito 84
HK - Hong Kong 44
CA - Canada 42
AT - Austria 37
VN - Vietnam 26
FI - Finlandia 25
FR - Francia 24
IN - India 23
BE - Belgio 18
TR - Turchia 16
DK - Danimarca 14
ID - Indonesia 7
JP - Giappone 7
PL - Polonia 7
IR - Iran 5
BG - Bulgaria 4
BR - Brasile 3
LT - Lituania 3
NL - Olanda 3
ES - Italia 2
EU - Europa 2
KR - Corea 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
CL - Cile 1
EE - Estonia 1
EG - Egitto 1
MA - Marocco 1
MK - Macedonia 1
MU - Mauritius 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
RO - Romania 1
SC - Seychelles 1
YE - Yemen 1
Totale 4.296
Città #
Ann Arbor 502
Frankfurt am Main 213
Fairfield 207
Chandler 206
Woodbridge 206
Dublin 187
Houston 146
Milan 140
Wilmington 136
Singapore 127
Ashburn 108
Dearborn 107
Jacksonville 89
Seattle 87
New York 78
Cambridge 74
Princeton 53
Santa Clara 50
Nanjing 47
Hong Kong 44
Vienna 36
Altamura 24
Lawrence 23
Shanghai 23
Nanchang 21
Beijing 19
Brussels 18
Lachine 15
San Diego 15
Boardman 14
Fremont 13
Göttingen 12
Guangzhou 11
Norwalk 10
Falls Church 9
Hangzhou 9
Lissone 9
Los Angeles 9
Andover 8
Helsinki 8
Ottawa 8
Toronto 8
Edmonton 7
Jakarta 7
Jiaxing 7
Lodz 7
Pune 7
Taizhou 7
Hebei 6
Kunming 6
London 6
Munich 6
Romola 6
Shenyang 6
Hefei 5
Jinan 5
Kiev 5
Kocaeli 5
Monza 5
Taku 5
Tianjin 5
Bucha 4
Cagliari 4
Changsha 4
Dong Ket 4
Fürstenwalde 4
Motta Di Livenza 4
Ningbo 4
Zhengzhou 4
Bonndorf 3
Boston 3
Cinisello Balsamo 3
Haikou 3
Nürnberg 3
Redmond 3
Trento 3
Acton 2
Bradford 2
Carate Brianza 2
Castiglione Delle Stiviere 2
Catania 2
Cesa 2
Changchun 2
Chicago 2
Chiswick 2
Daejeon 2
Delhi 2
Desio 2
Kilburn 2
Lanzhou 2
Lynnwood 2
Maarssen 2
Mississauga 2
Mountain View 2
Paris 2
Plovdiv 2
Quart de Poblet 2
Rome 2
Taiyuan 2
Torino 2
Totale 3.343
Nome #
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 354
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 289
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 270
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 242
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 224
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 208
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 200
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 200
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 196
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 189
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 177
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 164
Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth 163
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 159
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 144
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 127
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 126
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2 126
Crizotinib-resistan NPM-ALK mutants confer differential sensitivity to unrelated alk inhibitors 123
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 119
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency 112
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 110
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 110
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 90
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells 84
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target 66
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase 52
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase 49
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 40
Totale 4.513
Categoria #
all - tutte 15.341
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.341


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020566 0 0 0 0 72 101 126 63 84 51 53 16
2020/2021642 34 37 60 82 54 76 50 59 40 59 32 59
2021/2022353 27 33 24 13 30 40 20 25 18 39 32 52
2022/2023849 83 244 88 88 60 114 8 58 52 20 19 15
2023/2024523 16 18 24 25 58 169 101 12 36 9 2 53
2024/2025372 67 114 57 54 80 0 0 0 0 0 0 0
Totale 4.513